USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: DOR BIOPHARMA, INC.
City: PRINCETON
State: NJ
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,409,870.00 3

Award List:

Enteric-Coated Oral Beclomethasone Dipropionate in Patients with Acute Enteritis

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Christopher J. Schaber
Award Amount: $509,870.00
Abstract:
DESCRIPTION (provided by applicant): Acute radiation enteritis is caused by radiation-induced death of the normal cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and w eeks with chronic diarrhea, vomiting and… More

Beclomethasone post exposure therapy for gastrointestinal acute radiation syndrom

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kevin J. Horgan – 310-206-3580
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): This proposal concerns the use of beclomethasone dipropionate (BDP) as a post-exposure drug therapy having the potential to mitigate the gastrointestinal (GI) injury associated with acute radiation syndrome (ARS) following exposure to intense ionizing radiation.… More

IND 20212 (03-25-99) PHASE 2: ORBEC (ORAL BDP)-PATIENTS WITH CHRONIC GVHD

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kevin J. Horgan – 310-206-3580
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): Graft vs. Host Disease (GVHD) is an expensive life-threatening complication following allogeneic hematopoietic cell transplantation in some patients that receive this life-saving treatment for certain cancers. The proposed open-label, multi-center, two-part… More